Abstract
The number of hematopoietic stem cell transplants (HSCT) performed in the U.S. and worldwide is increasing. Cardiac events have been well described in HSCT, and incidence and type of cardiac events have not changed over recent decades. This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with risk of cardiac event (p = 0.005, p = 0.039, p = 0.038 respectively). Patients developing a CE had an increased risk of death within one year (11% vs. 32%, p
","abstract_html":"<p>Abstract</p> <p>The number of hematopoietic stem cell transplants (HSCT) performed in the U.S. and worldwide is increasing. Cardiac events have been well described in HSCT, and incidence and type of cardiac events have not changed over recent decades. This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with risk of cardiac event (p = 0.005, p = 0.039, p = 0.038 respectively). Patients developing a CE had an increased risk of death within one year (11% vs. 32%, p</p>","abstract_has_math":false,"creators":["Baker, Julie K"],"institution":null,"degree_name":"Doctor of Nursing Practice (DNP)","degree_level":"Open Access Thesis","degree_discipline":"Yale University School of Nursing","degree_department":null,"school":null,"contributors":["Jessica Coviello"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-01-01T08:00:00Z","date_published":"2019-01-01T08:00:00Z","updated_at":"2026-07-24T06:16:00Z","subjects":["Cardiotoxicity","Hematopoietic stem cell transplant","Risk assessment"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://elischolar.library.yale.edu/ysndt/1083","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Jessica Coviello"]},{"key":"dc:creator","label":"Author","values":["Baker, Julie K"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_discipline","label":"Discipline","values":["Yale University School of Nursing"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Open Access Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Nursing Practice (DNP)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cardiotoxicity","Hematopoietic stem cell transplant","Risk assessment"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://elischolar.library.yale.edu/ysndt/1083"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Abstract
The number of hematopoietic stem cell transplants (HSCT) performed in the U.S. and worldwide is increasing. Cardiac events have been well described in HSCT, and incidence and type of cardiac events have not changed over recent decades. This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with risk of cardiac event (p = 0.005, p = 0.039, p = 0.038 respectively). Patients developing a CE had an increased risk of death within one year (11% vs. 32%, p
"]},{"key":"dc:title","label":"Title","values":["Cardiotoxicity In Hematologic Stem Cell Transplant: Keeping The Beat"]}]}],"canonical_facts":{"dc:contributor":["Jessica Coviello"],"dc:creator":["Baker, Julie K"],"dc:description.abstract":["Abstract
The number of hematopoietic stem cell transplants (HSCT) performed in the U.S. and worldwide is increasing. Cardiac events have been well described in HSCT, and incidence and type of cardiac events have not changed over recent decades. This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with risk of cardiac event (p = 0.005, p = 0.039, p = 0.038 respectively). Patients developing a CE had an increased risk of death within one year (11% vs. 32%, p
"],"dc:identifier":["https://elischolar.library.yale.edu/ysndt/1083"],"dc:subject":["Cardiotoxicity","Hematopoietic stem cell transplant","Risk assessment"],"dc:title":["Cardiotoxicity In Hematologic Stem Cell Transplant: Keeping The Beat"],"thesis:degree_discipline":["Yale University School of Nursing"],"thesis:degree_level":["Open Access Thesis"],"thesis:degree_name":["Doctor of Nursing Practice (DNP)"]},"updated_at":"2026-07-24T06:16:00Z"}